WO2007102167A1 - A process for the preparation of anhydrous polymorphic form of olanzapine - Google Patents

A process for the preparation of anhydrous polymorphic form of olanzapine Download PDF

Info

Publication number
WO2007102167A1
WO2007102167A1 PCT/IN2006/000142 IN2006000142W WO2007102167A1 WO 2007102167 A1 WO2007102167 A1 WO 2007102167A1 IN 2006000142 W IN2006000142 W IN 2006000142W WO 2007102167 A1 WO2007102167 A1 WO 2007102167A1
Authority
WO
WIPO (PCT)
Prior art keywords
olanzapine
methyl
amino
cyano
thiophene
Prior art date
Application number
PCT/IN2006/000142
Other languages
French (fr)
Inventor
Venkat Reddy Alla
Kameswara Rao Vyakaranam
Aruna Kumari Sirigiri
Srinivas Reddy Bodapati
Ranadheer Reddy Billa
Raghumitra Alla
Original Assignee
Lee Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lee Pharma Limited filed Critical Lee Pharma Limited
Publication of WO2007102167A1 publication Critical patent/WO2007102167A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the invention pertains to the process of obtaining OLANZAPINE Form - II, having a process of preparation resulting in anhydrous form..
  • OLANZAPINE 2-methyl-4-(4-methyl-l-piperazinyl)-10H ⁇ thieno [2,3-b][l,5] benzodiazepine is useful in the treatment of psychotic disorders.
  • Oianzapine was described for the first time in the European Patent EP 0454436BI.
  • One of the methods for preparation of Olanzapine is based on condensation of 4-amino-2-methyl-10H- thieno [2,3-b][l, 5] benzodiazepine with N-methyl piperazine in dimethyl sulfoxide and toluene.
  • the typical methods for preparation of Olanzapine of technical grade comprise the condensation of 6-fold molar excess of N-methyl piperazine with 4-amino-2 methyl- 1 OH- thieno- [2, 3-b] [I. 5] benzodiazepine hydrochloride in an organic solvent, e. g. dimethylsulf oxide, to which alcohol and excess of water is added after the reaction is completed, to remove unreacted substrates and impurities. The product is separated in a form of solvate with alcohol.
  • OLANZAPINE is obtained.
  • the Patent No US 5,229,382 described first polymorph of OLANZAPINE called Form I, which has been described to be metastable and not suitable for commercial use in pharmaceutical formulations such as tablets due to its color which changes over time on exposure to air.
  • the patent EP 07336335 BI reported a more stable second polymorph of Olanzapine claimed as Olanzapine polymorphic Form II which is obtained by suspending crude Olanzapine in ethyl acetate in anhydrous conditions and crystallization from this solution.
  • the existence of the two different polymorphs (Form I and Form II) has been confirmed by X ray powder diffraction patterns characterized by different interplanar spacing d and relative intensities I/Io.
  • Preparation methods were also given for a polymorph defined by the Applicant as Olanzapine Form I, by crystallization of crude Olanzapine from acetone (Preparation 5), tetrahydrofuran (Preparation 6), ethyl acetate (Preparation 7), t-butanol (Preparation 8).
  • EP 0733637 described preparation of solvate Form of Olanzapine From-II.
  • the shortcomings of earlier inventions are addressed in the present invention and a more convenient, reproducible process is described.
  • the main objective of this invention is to develop a better method of preparation for anhydrous OLANZAPINE of Form -II.
  • Step-II 4-Cyano-2-methyl-l- (2-Nitro phenyl amino) Thiophene
  • Step-III 4-amino-2-methyl-10H-Thieno [2,3-b][l,5] Benzodiazepine
  • This invention describes an improved method for the preparation of anhydrous OLANZAPINE of Form II
  • Anhydrous OLANZAPINE (Technical grade) is dissolved in Acetone at a temperature ranging from 40° C to 65° C , preferably at 50° C -60° C more preferably in the range of 55° C-58° C .
  • the ratio of Technical Olanzapine and Acetone may be 1: 10, preferably 1:7.5 and more preferably 1:5.
  • the resultant clear solution is then treated with activated carbon and stirred for 60 minutes.
  • the solvent is distilled off completely under reduced pressure.
  • An anti solvent is added and the resultant solid is filtered.
  • the anti solvent may be a lower alcohol preferably C 1 to C2; more preferably methanol.
  • the product is dried generally C 1- C4 at 65°C-70°C till constant weight.
  • the Olanzapine Form-II thus obtained was investigated by Elemental analysis, Ultra-violet spectrophotometer. Infrared absorption spectrophotometer, Proton nuclear magnetic resonance spectrometer, Carbon magnetic resonance spectrometer and mass spectrometer.
  • the polymorphism is established by the X Ray Diffraction values and are compared with the reported values. Below is the comparison of d- values of Form-II produced by the inventor and reported values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Malononitrile is reacted with Propionaldehyde in presence of Sulphur Powder and Triethylamine in N,N-dimethlyformamide to give 5-Amino4- Cyano-2 -Methyl Thiophene. 2-fluoronitrobenzene is condensed with 5- Amino-4-Cyano-2-Methyl Thiophene in Isopropyl alcohol and Potassium Hydroxide powder give 4-cyano-2-methyl-1-(2-nitrophenyl amino) Thiophene. Reduction of 4-cyano-2-methyl-1-(2-nitrophenyl amino) Thiophene with Stannous Chloride and Hydrochloric acid in Isopropyl; Alcohol and followed by cyclization to get 4-Amino-2-Methyl-10H- Thieno [2,3,-b][1,5] Benzodiazepine Condensation of 4-amino-2-methyF10H-Thieno [2,3,-b][1,5] Benzodiazepine and N-methyl Piperazine in presence of Dimethyl Sulphoxide and Toluene gives Olanzapine Technical grade, in anhydrous form. Treatment of anhydrous technical Olanzapine with acetone followed by subsequent precipitation with an anti solvent gave anhydrous OLANZAPINE of Form-II.

Description

TITLE:
A process for the preparation of anhydrous polymorphic form of olanzapine.
FIELD OF INVENTION:
The invention pertains to the process of obtaining OLANZAPINE Form - II, having a process of preparation resulting in anhydrous form..
BACKGROUND OF THE INVENTION:
OLANZAPINE, 2-methyl-4-(4-methyl-l-piperazinyl)-10H~thieno [2,3-b][l,5] benzodiazepine is useful in the treatment of psychotic disorders.
PRIOR ART:
A few patents have described the method of preparation of Olanzapine Form II but this invention provides a more convenient method for preparation of anhydrous Olanzapine Form II commercially.
Oianzapine was described for the first time in the European Patent EP 0454436BI. One of the methods for preparation of Olanzapine is based on condensation of 4-amino-2-methyl-10H- thieno [2,3-b][l, 5] benzodiazepine with N-methyl piperazine in dimethyl sulfoxide and toluene.
US 5229382 invention described the preparation of Olanzapine and did not mention any of the Forms. It only relateed to another property of the Compound and the formulations corresponding to it.
In Various patents and patent applications, the typical methods for preparation of Olanzapine of technical grade comprise the condensation of 6-fold molar excess of N-methyl piperazine with 4-amino-2 methyl- 1 OH- thieno- [2, 3-b] [I. 5] benzodiazepine hydrochloride in an organic solvent, e. g. dimethylsulf oxide, to which alcohol and excess of water is added after the reaction is completed, to remove unreacted substrates and impurities. The product is separated in a form of solvate with alcohol. Depending on the method used for the purification of technical grade Olanzapine, pharmaceutical grade of OLANZAPINE is obtained.
The Patent No US 5,229,382 described first polymorph of OLANZAPINE called Form I, which has been described to be metastable and not suitable for commercial use in pharmaceutical formulations such as tablets due to its color which changes over time on exposure to air.
The patent EP 07336335 BI reported a more stable second polymorph of Olanzapine claimed as Olanzapine polymorphic Form II which is obtained by suspending crude Olanzapine in ethyl acetate in anhydrous conditions and crystallization from this solution. The existence of the two different polymorphs (Form I and Form II) has been confirmed by X ray powder diffraction patterns characterized by different interplanar spacing d and relative intensities I/Io.
In the methods described above use of different solvents was required at the subsequent steps of isolation and purification of technical grade Olanzapine. Moreover, these methods are rather difficult to repeat and often do not lead to obtaining the required polymorphic form consistently. For example, following the procedure of Preparation 1 of European Patent EP 0828494., comprising suspending the crude Olanzapine in a very small amount of Methylene chloride, filtration off the precipitate, then its maceration with Methylene chloride and drying, the obtaining of crystalline Form II solvate with Methylene chloride is declared in the said patent. Preparation methods were also given for a polymorph defined by the Applicant as Olanzapine Form I, by crystallization of crude Olanzapine from acetone (Preparation 5), tetrahydrofuran (Preparation 6), ethyl acetate (Preparation 7), t-butanol (Preparation 8).
But, in WO03097650 it is described that the use of any solvent such as acetonitnile, tetrahydrofuran, acetone, toluene or ethyl acetate for crystallization of crude Olanzapine always results in Form-II only as identified by X-ray powder diffraction patterns described in EP 0733635.
There were several other patents that described the preparation of Olanzapine Form-II.
US 5736541 described pure solvate free anhydrous Olanzapine From- II. The method of preparation is described.
US 5919485 described preparation of Olanzapine Form-II from ethyl acetate
EP 0733637 described preparation of solvate Form of Olanzapine From-II.
OBJECTS OF THE INVENTION:
The following shortcomings were observed in using the methods described earlier for the preparation of OLANZAPINE Form II.
i) The OLANZAPINE Form II prepared in any of the known processes is obtained by double or multiple crystallisations only.
ii) The patents and publications available have described the method of preparation of OLANZAPINE Form II only crystallisation from ethyl acetate.
The shortcomings of earlier inventions are addressed in the present invention and a more convenient, reproducible process is described. The main objective of this invention is to develop a better method of preparation for anhydrous OLANZAPINE of Form -II.
The above and other objectives and advantages will be clear from the following description of the preferred embodiment.
The foregoing description is outlined, rather broadly preferred and alternatively featured, of the present invention so that those skilled in the art may better understand the detailed description of the invention that follows,
Additional features of the invention will be described hereinafter that form the subject of claims of the invention. Those skilled in the art should appreciate that they can readily use the disclosed concept and specific embodiment as a basis for carrying out the same purposes of the present invention. Those skilled in the art should realize that such equivalent conception do not depart from the spirit and scope of the invention in its broadest sense.
SUMMARY OF THE INVENTION:
An alternative method for the preparation of anhydrous OLANZAPINE of Form- II is described.
Step-I: 5-amino-4-cyano-2-methyl thiophene
Malononitrile is reacted with Propionaldehyde in presence of Sulphur
Powder and Trieethylamine in N,N-dimethlyformamide to give 5-Amino-4- Cyano-2-Methy Thiophene
Step-II: 4-Cyano-2-methyl-l- (2-Nitro phenyl amino) Thiophene
2-fluoronitrobenzene is condensed with 5-Amino-4 Cyano-2-Methy] Thiophene in Isopropyl alcohol and Potassium Hydroxide powder give 4- cyano-2-methy l-(2-nitrophenyl amino) Thiophene
Step-III: 4-amino-2-methyl-10H-Thieno [2,3-b][l,5] Benzodiazepine
Reduction of 4-cyano-2-methyl-l-(2-nitrophenyl amino) Thiophene with Stannous Chloride and Hydrochloric acid in Isopropyl Alcohol and followed by cyclization to get 4-Amino-2-Methyl-10H-Thieno [2,3, -bill ,5] Benzodiazepine .
Step-IV: Olanzapine Technical grade
Condensation of 4-amino-2-methyl- 10H-Thieno [2,3,-b][l,5]
Benzodiazepine and N-methyl Piperazine in presence of Dimethyl Sulfoxide and Toluene gives Olanzapine Technical grade in anhydrous form.
Step-V: Olanzapine Form-II
Technical grade anhydrous Olanzapine is connected to Olanzapine Form- II By controlled treatment Acetone and an anti solvent.
DESCRIPTION OF THE INVENTION
Now the invention will describe in detail with reference to the chemical drawings herein provided for easy reference to overcome the shortcomings of the prior art available with the same process, and this invention was made.
This invention describes an improved method for the preparation of anhydrous OLANZAPINE of Form II
Figure imgf000007_0001
5-amino-4-cyano- 2-methyl thiophene
Reaction of Malononitrile with Propionaldehyde in presence of Sulphur Powder and Triethylamine in N, N-dimethlyformamide gives 5-Amino- 4-Cyano-2 -Methyl Thiophene as per the procedure described in EP 0454436A1
H2
Figure imgf000007_0002
5-amino-4-cyano- lsopropyl alcohol
4-cyano-2-methyl-1-(2-Nitrophenylamino) 2-methyl thiophene Thiophene. 2-fluoronitrobenzene is condensed with 6-Amino-4-Cyano-2-Methyl Thiophene in Isopropyl alcohol and Potassium Hydroxide powder to get 4- cyano -2- methyl- l-(2-nitrophenyl amino) Thiophene.
Stannous chloride
Isopropyl alcohol
Figure imgf000008_0001
4-cyano-2-methyl-1-(2-Nitrophenylamino) Hydrochloric acid Thiophene.
Figure imgf000008_0002
4-amino-2-methyl-10H-Thieno [2,3-b][1 ,5] Benzodiazepine hydrochloride
Reduction of 4-cyano-2-methyl-l-(2-nitrophenyl amino) Thiophene with Stannous Chloride and Hydrochloric acid in Isopropyl Alcohol and followed by cyclization to get 4-Amino-2 -Methyl- 10H-Thieno [2,3,-b][l,5] Benzodiazepine using the same procedure as described in EP 0454436A1 but using Isopropyl alcohol in place of Ethanol
N-Methyl piperazine Toluene
Dimethyl sulfoxide
Figure imgf000008_0004
DM water
Figure imgf000008_0003
4-amino-2-methyl-1 OH-Thieno [2,3-b][1 ,5] Benzodiazepine hydrochloride Condensation of 4-amino-2-methyl-10H-Thieno [2,3,-b][l,5]
Benzodiazepine and N-methyl Piperazine in presence of Dimethyl Sulfoxide and Toluene gives Olanzapine Technical grade by following same procedure as described in EP 0454436A1.
DESCRIPTION OF THE PREFERRED EMBODIMENT:
Treatment of Technical grade anhydrous Olanzapine with Acetone and subsequent precipitate with an anti solvent gives anhydrous Olanzapine Form-II and is carried out according to the procedure described below.
Anhydrous OLANZAPINE (Technical grade) is dissolved in Acetone at a temperature ranging from 40° C to 65° C , preferably at 50° C -60° C more preferably in the range of 55° C-58° C . The ratio of Technical Olanzapine and Acetone may be 1: 10, preferably 1:7.5 and more preferably 1:5. The resultant clear solution is then treated with activated carbon and stirred for 60 minutes.
It is then filtered and the clear filtrate is collected into a separate vessel. The solvent is distilled off completely under reduced pressure. An anti solvent is added and the resultant solid is filtered. The anti solvent may be a lower alcohol preferably C1 to C2; more preferably methanol. The product is dried generally C1- C4 at 65°C-70°C till constant weight.
It will be understood that the aforesaid description is only illustrative of the present invention and is not intended that the present invention is limited thereto. Many other specific embodiments of the present invention will be apparent to one skilled in the art from the foregoing disclosure. Any substitution, alteration or modifications of the present invention, which come within the scope of claims, are to which the present invention is readily susceptible without departing from the spirit of invention. Characterization of the Olanzapine as prepared aforesaid is done as follows:
For Elucidation of Structure, the Olanzapine Form-II thus obtained was investigated by Elemental analysis, Ultra-violet spectrophotometer. Infrared absorption spectrophotometer, Proton nuclear magnetic resonance spectrometer, Carbon magnetic resonance spectrometer and mass spectrometer.
The polymorphism is established by the X Ray Diffraction values and are compared with the reported values. Below is the comparison of d- values of Form-II produced by the inventor and reported values.
Figure imgf000011_0001

Claims

CLAIMS:
01. A process for the preparation of OLANZAPINE of Form- II by,
a) Treating Technical grade anhydrous Olanzapine with Acetone and subsequent precipitation in an anti solvent to give
Olanzapine Form-II.
02. A process for the preparation of OLANZAPINE of Form- II as claimed in claim 1 , wherein the resultant product is anhydrous.
PCT/IN2006/000142 2006-03-06 2006-04-25 A process for the preparation of anhydrous polymorphic form of olanzapine WO2007102167A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN390/CHE/2006 2006-03-06
IN390CH2006 2006-03-06

Publications (1)

Publication Number Publication Date
WO2007102167A1 true WO2007102167A1 (en) 2007-09-13

Family

ID=38474635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000142 WO2007102167A1 (en) 2006-03-06 2006-04-25 A process for the preparation of anhydrous polymorphic form of olanzapine

Country Status (1)

Country Link
WO (1) WO2007102167A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225941A (en) * 2011-06-01 2011-10-26 宁波人健医药化工有限公司 Preparation method of antipsychotic drug olanzapine
CN102276624A (en) * 2011-06-17 2011-12-14 大连理工大学 Olanzapine related substance and preparation method as well as high-efficiency liquid-phase chromatographic analysis method thereof
CN103848847A (en) * 2012-12-04 2014-06-11 广东东阳光药业有限公司 Improved method for preparing olanzapine and crystal form II thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097650A1 (en) * 2002-05-17 2003-11-27 Institut Farmaceutyczny Methods for preparation of olanzapine polymorphic form i
WO2006030300A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Processes for the preparation of olanzapine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097650A1 (en) * 2002-05-17 2003-11-27 Institut Farmaceutyczny Methods for preparation of olanzapine polymorphic form i
WO2006030300A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Processes for the preparation of olanzapine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225941A (en) * 2011-06-01 2011-10-26 宁波人健医药化工有限公司 Preparation method of antipsychotic drug olanzapine
CN102225941B (en) * 2011-06-01 2013-11-27 宁波人健医药化工有限公司 Preparation method of antipsychotic drug olanzapine
CN102276624A (en) * 2011-06-17 2011-12-14 大连理工大学 Olanzapine related substance and preparation method as well as high-efficiency liquid-phase chromatographic analysis method thereof
CN103848847A (en) * 2012-12-04 2014-06-11 广东东阳光药业有限公司 Improved method for preparing olanzapine and crystal form II thereof
CN103848847B (en) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 A kind of method that improvement prepares Olanzapine and its crystal formation II

Similar Documents

Publication Publication Date Title
EP1313742A1 (en) Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US8063214B2 (en) Polymorphic forms of tadalafil
EP0831098B1 (en) Intermediates and process for preparing olanzapine
CA2495823A1 (en) Method for manufacturing crystalline form i of clopidogrel hydrogen sulphate
US20040242556A1 (en) Novel crystalline form of cefdinir
WO2007094006A1 (en) Process for preparation of clopidogrel bisulfate form 1
EP1509531A1 (en) Methods for preparation of olanzapine polymorphic form i
WO2007102167A1 (en) A process for the preparation of anhydrous polymorphic form of olanzapine
HRP20050039A2 (en) Crystal forms of olanzapine and processes for their preparation
CN110114346A (en) It is used to prepare R-6- hydroxyl -8- [1- hydroxyl -2- [2- (4- methoxyphenyl) -1,1- dimethyl-ethylamino ethyl] -2H-1, the improved method of 4- benzoxazine -3 (4H) -one hydrochloride
US7834176B2 (en) Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7829700B2 (en) Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
ITMI20090663A1 (en) PROCEDURE FOR THE PURIFICATION OF PALIPERIDONE
SI21850A (en) Salts of olanzapin and their transformation into free base of olanzapin
WO2006025065A1 (en) A process for the preparation of anhydrous olanzopine hydrochloride of form-1
US20060019937A1 (en) Novel crystalline forms of 6alpha, 9alpha -difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene 17beta-carboxylic acid and processes for preparation thereof
KR20100016419A (en) Crystalline forms of topotecan hydrochloride and processes for making the same
US20090131658A1 (en) Process for preparing Olanzapine form I
WO2005080401A1 (en) Process for the preparation of olanzapine form 1 useful as antipsychotic drug
WO2007096895A1 (en) Preparation of anhydrous olanzapine of form-1
KR101489062B1 (en) Process for the preparation of high purity olanzapine and crystalline form II thereof
SI21746A (en) Crystal forms of olanzapine and processes for their preparation
ZA200301640B (en) Process for preparation of hydrates of Olanzapine and their conversion into cystalline forms of Olanzapine.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS (1205A SENT 12-11-2008, 04-12-2008)

122 Ep: pct application non-entry in european phase

Ref document number: 06745213

Country of ref document: EP

Kind code of ref document: A1